Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections

References

• Ortho-McNeil Pharmaceutical. Levaquin® (levofloxacin) prescribing information. Revised August 2005. Available from http://www.levaquin.com [Last accessed 21 February 2006]
   Google Scholar
• West M, Boulnager BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485–506
   PubMed Web of Science ®Google Scholar
• Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002;35:381–9
   PubMed Web of Science ®Google Scholar
• Poole M, Anon J, Paglia M, et al. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 2006;134:10–7
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001–10
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752–60
   PubMed Web of Science ®Google Scholar
• Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483–90
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073–81
   PubMed Web of Science ®Google Scholar
• Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against cipro-floxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:43–9
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002;62:13–59
   PubMed Web of Science ®Google Scholar
• Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112: 275–85
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590–7
   PubMed Web of Science ®Google Scholar
• Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. Philadelphia: Elsevier, 2004
   Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. New Engl J Med 2006;354:1352–61
   PubMed Web of Science ®Google Scholar
• Happe MR, Mulhall BP, Maydonovitch CL, et al. Gatifloxacin-induced hyperglycemia. Ann Intern Med 2004;141:968–9
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 2004;141:969
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. BMI – body mass index: BMI for adults. Available from http://www.cdc.gov/nccdphp/dnpa/bmi/bmi-adult.htm [Last accessed 21 February 2006]
   Google Scholar
• Adelglass J, Jones TM, Ruoff G, et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998;18:1255–63
   PubMed Web of Science ®Google Scholar
• Adelglass J, DeAbate A, McElvaine P, et al. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999;120:320–7
   PubMed Web of Science ®Google Scholar
• Syndor TA, Kopp EJ, Anthony KE, et al. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998;80:357–62
   PubMed Web of Science ®Google Scholar
• Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infectious Diseases in Clinical Practice 1998;7:101–9
   Google Scholar
• DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206–13
   Google Scholar
• Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292–308
   PubMed Web of Science ®Google Scholar
• Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38(Suppl 1):S16–23
   Google Scholar
• Fogarty CM, Sullivan JG, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infectious Diseases in Clinical Practice 1998;7:400–7
   Web of Science ®Google Scholar
• File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime/axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965–72
   PubMed Web of Science ®Google Scholar
• Akpunonu B, Michaelis J, Uy C, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004;38 (Suppl 1):S5–15
   Google Scholar